康恩贝子公司氨甲环酸片获得药品注册证书

Core Viewpoint - Kangnibei (600572.SH) has received approval from the National Medical Products Administration for its subsidiary Hangzhou Kangnibei Pharmaceutical Co., Ltd. to market a 0.25g specification of Tranexamic Acid Tablets [1] Group 1 - The original manufacturer of Tranexamic Acid Tablets is Daiichi Sankyo Co., Ltd. from Japan, which has approved both 0.25g and 0.5g specifications in Japan, with the 0.5g specification already approved for sale in China [1] - Tranexamic Acid Tablets are primarily used for treating various bleeding conditions caused by acute or chronic, localized or systemic primary fibrinolysis, as well as secondary hyperfibrinolytic states due to disseminated intravascular coagulation [1]